Association of obesity with ropivacaine and sufentanil EC50 in labor analgesia: a single-center prospective study
- PMID: 39774874
- DOI: 10.1007/s00228-024-03800-8
Association of obesity with ropivacaine and sufentanil EC50 in labor analgesia: a single-center prospective study
Abstract
Objective: In part I, measure the EC50 of sufentanil in obese and non-obese parturients combined with 0.1% ropivacaine and compare the differences. Similarly, in part II, measure the EC50 of ropivacaine in obese and non-obese parturients combined with 0.5 µg/ml sufentanil and compare the differences.
Methods: This study comprises two parts, with an initial intention to enroll 120 full-term primiparous women who underwent vaginal delivery and sought epidural analgesia. Each part includes an obese group (OA group, Obese Adults, defined as prepartum BMI≥29 kg/m2) and a non-obese group (CON group, Control group, defined as 18.5<prepartum BMI<28 kg/m2), with 30 participants in each. Both parts, for both obese and non-obese women, utilized an initial concentration of 0.1% ropivacaine with 0.5 µg /ml sufentanil. The initial concentration of sufentanil is 0.5 µg/ml. When the NRS score is ≤3 within 30min after analgesia, it is considered effective analgesia, and the concentration of sufentanil in the next parturients decreases by 0.05 µg/ml. Otherwise, the concentration of sufentanil in the next parturient will increase by 0.05 µg/ml. The second part uses the same method to measure the EC50 of ropivacaine (increase or decrease by 0.01%) in the OA group and CON group combined with 0.5 µg/ml sufentanil, with 30 participants in each group. EC50 measurements were performed through up-and-down sequential allocation, with effective analgesia defined as an NRS score ≤3, 30 min post-analgesia.
Results: In part I, the EC50 of epidural sufentanil in the OA group was 0.090 µg/ml (95% CI, 0.061~0.115µg/ml), and in the CON group, it was 0.170µg/ml (95% CI, 0.117~0.219µg/ml). In part II, the EC50 of epidural ropivacaine in the OA group was 0.048% (95% CI, 0.041~0.053%), and in the CON group, it was 0.070% (95% CI, 0.064~0.075%). The secondary outcomes in both parts of the study showed no statistically significant differences.
Conclusion: Obese parturients exhibited significantly lower EC50 values for ropivacaine and sufentanil compared to non-obese parturients. Lower concentrations of both agents can be considered for labor analgesia in obese parturients.
Keywords: Obese parturients; Epidural labor analgesia; EC50; Dose–response relationship.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Lobstein T, Brinsden H, Neveux M (2022) World obesity atlas 2022.World obesity federation; Available at: https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_202... . Accessed 12 July 2023
-
- Yu H, Li M, Qian G, Yue S, Ossowski Z, Szumilewicz A (2024) A systematic review and Bayesian network meta-analysis comparing in-person, remote, and blended interventions in physical activity, diet education and behavioral modification on gestational weight gain among overweight or obese pregnant individuals. Adv Nutr 15(7):100253 - DOI - PubMed - PMC
-
- Amadou A, Ferrari P, Muwonge R et al (2024) Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev 14(8):665–678 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
